Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The t(11;14)/CCND1-IGH, t(4;14)/NSD2(MMSET)-IGH, and t(14;16)/IGH-MAF gene rearrangements detected by fluorescence in situ hybridization (FISH) are used for risk stratification in patients with multiple myeloma (MM).
|
31218784 |
2019 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
TSA exerted a time and dose-dependent cytotoxicity on MM cell lines, and suppressed the proliferation of MM cells and induced an upregulation of p21 protein accompanied by a decreased expression of cyclin D1.
|
30214285 |
2018 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Moreover, a known miR-28-5p target, CCND1, was expressed at higher levels in HMCLs with LPP/miR-28 methylation than those without, consistent with a tumour suppressor role of miR-28-5p in myeloma.
|
28775176 |
2018 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms.
|
29403080 |
2018 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Cyclin D1 is a more prominent driver in AL amyloidosis than in MM, but the links to aggregation of light chains need to be demonstrated.
|
28025584 |
2017 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We established several clones that constitutively express cyclin D1 from the parental RPMI8226 MM cell line and analyzed the impact of cyclin D1 expression on cell behavior.
|
27286258 |
2016 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We applied ND and MM-MSCs 72h secretomes to MM cell lines (U266 and ARP-1) for 12-72h and then assayed the cells' (viability, cell count, cell death, proliferation, cell cycle, autophagy) and TI (factors: eIF4E, teIF4GI; regulators: mTOR, MNK1/2, 4EBP; targets: cyclin D1, NFκB, SMAD5, cMyc, HIF1α).
|
26976208 |
2016 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In total, 98 patients were included in this retrospective translational research study and were evaluated for Kirsten rat sarcoma viral oncogene homolog (KRAS) mutational status, and v-akt murine thymoma viral oncogene homolog 1 (AKT1), AKT serine/threonine kinase 2 (AKT2), AKT serine/threonine kinase 3 (AKT3), cyclin D1 (CCND1), epidermal growth factor receptor (EGFR), mitogen-activated protein kinase 1 (MAPK1), hepatocellular growth factor receptor (MET), avian myelomatosis viral oncogene homolog (MYC), nuclear factor kappa B subunit 1 (NFKb1), phosphatase and tensin homolog (PTEN) and mechanistic target of rapamycin (FRAP1) genes mRNA expression.
|
27919956 |
2016 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Translocation t(11;14)(q13;q32) CCND1-IGH is typically associated with mantle cell lymphoma or a subset of plasma cell myeloma and is exceedingly rare in myeloid neoplasm.
|
27810077 |
2016 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We used two independent MM cell lines (RPMI 8226 and LP1) to generate several clones stably expressing either the green fluorescent protein (GFP) or a GFP-cyclin D1 fusion protein, and we analyzed the properties acquired following cyclin D1 expression.
|
25881299 |
2015 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We showed tetraspanins attenuated peIF4E and its targets [c‑Myc, cyclin D1 (cycD1)]; eIF4E attenuation was Akt-dependent. eIF4E inhibition in MM cells [bone marrow (BM), lines] by siRNA and/or the anti‑viral drug and competitive eIF4E inhibitor ribavirin (RBV) deleteriously affected MM cells in a similar manner to the overexpression of tetraspanins.
|
25422161 |
2015 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the CCND1 G870A SNP may be critically involved in MM development.
|
26125784 |
2015 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Cyclin D1 gene amplification was found in 20% of myeloma patients and was associated with higher percentage of plasma cell infiltration of the bone marrow and increased liability for multiple osteolytic lesions.
|
24468132 |
2014 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
GWASCAT |
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.
|
23502783 |
2013 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Among recurrent IGH translocations in MM, the frequency of t(4;14) (IGH and FGFR3) or t(11;14) (IGH and CCND1) is greater than the frequency of t(14;16) (IGH and MAF).
|
23460268 |
2013 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We found that target genes of the most differentially expressed miRNAs are directly involved in the pathogenesis of MM; specifically, the inhibition of hsa-miR-425, hsa-miR-152 and hsa-miR-24, which are all downregulated in h-MM, leads to the overexpression of CCND1, TACC3, MAFB, FGFR3 and MYC, which are the also the oncogenes upregulated by the most frequent IgH chromosomal translocations occurring in nh-MM.
|
23174883 |
2013 |
Multiple Myeloma
|
0.700 |
SusceptibilityMutation
|
disease |
ORPHANET |
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.
|
23502783 |
2013 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
GWASDB |
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.
|
23502783 |
2013 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
CTD_human |
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.
|
23502783 |
2013 |
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.
|
23502783 |
2013 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Combination of seliciclib with flavopiridol effectively reduced CCNE1 and CCND1 protein levels, increased subG1 apoptotic fraction and promoted MM cell death in BMSCs co-culture conditions, therefore over-coming stroma-mediated protection.
|
22558078 |
2012 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents.
|
22565393 |
2012 |
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
A variety of patterns of the IgH deletion were identified by interphase FISH using IgH break-apart and IgH/CCND1 probes in patients with MM and CLL.
|
21272268 |
2011 |
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Our study is the first to suggest that overexpressed CCND1 in MM is an independent prognostic marker associated with a more durable response to bortezomib.
|
20578819 |
2010 |
Multiple Myeloma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
To our knowledge, this is the first case showing amplification of the IGH/CCND1 gene in plasma cell neoplasms.
|
20633772 |
2010 |